<section class="eo-description">
  <h2>Expert Opinion Description</h2>
    <ul>
      <li>Something goes here</li>
      <li>Something goes here</li>
      <li>Something goes here</li>
      <li>Something goes here</li>
    </ul>
    <ol>
      <li>Something goes here</li>
      <li>Something goes here</li>
      <li>Something goes here</li>
      <li>Something goes here</li>
    </ol>
  <p>In a phase III trial, patients with metastatic colorectal cancer who failed first-line oxaliplatin-based therapy had improved survival with second-line FOLFIRI plus the antiangiogenic agent aflibercept, compared with second-line FOLFIRI alone.</p>
</section><!--/.eo-description-->